Informing health system planning for biomarker-based treatment: statistical prevalence projections for solid cancers with key pan-tumour biomarkers (dMMR, MSI, high TMB) in Australia to 2042.

ABSTRACT:

Background

Targeted cancer treatment based on mismatch repair deficiency (dMMR), microsatellite instability (MSI), or high tumour mutational burden (TMB) holds promise for improving patient outcomes, but presents substantial healthcare costs.

Methods

Using validated statistical methods, we projected 1-year to 5-year prevalence of individuals diagnosed with solid tumours exhibiting these biomarkers in Australia to 2042, for all solid cancers combined and 23 individual cancer types/groups, and separately for all stages combined, advanced disease at diagnosis (here, distant metastasis/lymph node involvement), and advanced disease after progression post-diagnosis.

Findings

The 5-year prevalence of individuals diagnosed with any solid cancer regardless of biomarker status

SUBMITTER: Kang YJ 

PROVIDER: S-EPMC12002892 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature